Q-omics provides the consensus-scored NME2 profile across patient tissues and cancer cell-line models. NME2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NME2 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, NME2 RNA expression shows 16,936 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRP as cancer lineages where NME2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NME2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NME2 survival associations across molecular data types. NME2 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NME2 RNA expression–survival associations across cancer types. High NME2 expression shows unfavorable associations in ACC, KIRC, CESC, KIRP, LGG and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NME2 RNA expression.
This table summarizes NME2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NME2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NME2 shows higher tumor expression in KIRP, BLCA, KIRC, HNSC, COAD and LUAD. The KIRP box plot shows higher NME2 RNA expression in tumor versus normal tissue (log2 FC = +1.974, t-test p < 0.001).
This table shows molecular features associated with NME2 in patient tissues and cancer cell lines. In patient samples, NME2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NME2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
